Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
drugs such as Novo Nordisk's Ozempic, the Danish Medicines Agency said on Wednesday. In 2023, 50% of new patients suffering from type 2 diabetes began treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first, the Medicines Agency said. Demand for Novo Nordisk's diabetes drug Ozempic has soared as many people have started using the diabetes drug for its weight-loss effects. Doctors and other prescribers in the UK were in July ordered to stop prescribing Ozempic to people who don't have type 2 diabetes, following a national shortage of GLP-1 drugs due to the soaring demand for approved and off-label use. The Danish Medicines Agency expects nearly half of all those currently using GLP-1 drugs to switch to cheaper alternatives, but said it would continue to reimburse patients for their GLP-1 drugs, if they cannot be treated with the cheaper counterparts. The drugs that will be affected by Denmark's new regulation when it enters into force on Nov. 25 this
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down [Yahoo! Finance]Yahoo! Finance
- If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today [Yahoo! Finance]Yahoo! Finance
- Why Lilly And Novo Nordisk Will Keep Dominating The Market For Blockbuster GLP-1 Drugs [Forbes]Forbes
- ‘Ozempic Week' Ad Campaign Backfires for Delivery Service Gopuff [BNN Bloomberg (Canada)]BNN Bloomberg
- TriSalus Reports Q1 2024 Financial Results and Business Update [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- 5/13/24 - Form 6-K
- NVO's page on the SEC website